RT Journal Article
T1 Persistent low-Level viremia in persons living with HIV undertreatment: an unresolved status
A1 Crespo Bermejo, Celia
A1 Ramírez de Arellano, Eva
A1 Lara Aguilar, Violeta
A1 Valle Millares, Daniel
A1 Gómez-Lus Centelles, María Luisa
A1 Madrid González, Ricardo
A1 Martín Carbonero, Luz
A1 Briz Sebastián, Verónica
AB Antiretroviral therapy (ART) allows suppressed viremia to reach less than 50 copies/mL in most treated persons living with HIV (PLWH). However, the existence of PLWH that show events of persistent low-level viremia (pLLV) between 50 and 1000 copies/mL and with different virological consequences have been observed. PLLV has been associated with higher virological failure (VF), viral genotype resistance, adherence difficulties and AIDS events. Moreover, some reports show that pLLV status can lead to residual immune activation and inflammation, with an increased risk of immunovirological failure and a pro-inflammatory cytokine level which can lead to a higher occurrence of non-AIDS defining events (NADEs) and other adverse clinical outcomes. Until now, however, published data have shown controversial results that hinder understanding of the true cause(s) and origin(s) of this phenomenon. Molecular mechanisms related to viral reservoir size and clonal expansion have been suggested as the possible origin of pLLV. This review aims to assess recent findings to provide a global view of the role of pLLV in PLWH and the impact this status may cause on the clinical progression of these patients.
PB Taylor & Francis Open Access
SN 2150-5594, Electronic: 2150-5608
YR 2021
FD 2021-12-07
LK https://hdl.handle.net/20.500.14352/4920
UL https://hdl.handle.net/20.500.14352/4920
LA eng
NO Crespo-Bermejo, Celia, et al. «Persistent Low-Level Viremia in Persons Living with HIV Undertreatment: An Unresolved Status». Virulence, vol. 12, n.o 1, diciembre de 2021, pp. 2919-31. DOI.org (Crossref), https://doi.org/10.1080/21505594.2021.2004743.
NO Instituto de Salud Carlos III
NO Comunidad de Madrid
DS Docta Complutense
RD 25 may 2025